Teva Pharmaceutical Industries

NYSE: TEVA
$13.19
-$0.12 (-0.9%)
Closing price February 21, 2020

Why Teva’s Grand Turnaround Could Just Be Getting Started

It seems to have been a long time since there were all that many positive statements about Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). But a look through the slew of ...
Read Full Story »

Top Analyst Upgrades and Downgrades: AbbVie, Apple, Arconic, CenturyLink, eHealth, Nvidia, Salesforce, Tesla, Teva and More

Stocks were close to all-time highs last Friday ahead of the three-day weekend, despite the coronavirus news getting worse, but the news from Apple has sent the stock indexes lower ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Applied Materials, Cisco, Cognizant, Costco, Enphase, Medtronic, Shopify, Starbucks, Teva, Xilinx and More

Stocks have risen and risen, with all three major U.S. indexes hitting new highs, but profit-taking and more coronavirus news dominated the headlines on Thursday morning. Many investors have yet ...
Read Full Story »

Cisco, CVS, Lyft, Nvidia, Shopify, Roku and More Major Earnings Coming This Week

The fourth-quarter earnings reporting season has reached a peak, but many more major companies will be sharing their results soon. With the coronavirus, China and impeachment dominating the news flow, ...
Read Full Story »

Will Teva Stock Collapse Before It Fixes Its Problems?

Teva Pharmaceuticals Industries Ltd. (NASDAQ: TEVA), the generic drug company, was founded in 1901 in Israel. It has become one of the largest pharmaceutical companies in the world. Teva recently ...
Read Full Story »

Short Sellers Can’t Make Up Their Mind on Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Shy Away From Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Big Pharma Short Sellers Get Selective

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Big Pharma Short Sellers Grow More Selective

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Big Pharma Short Sellers Hike Their Bets

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Albermarle, Amgen, Applied Materials, Biogen, CRISPR, CrowdStrike, CSX, Kroger, Slack, Teva, Xerox and More

Stocks were mixed in the premarket on Tuesday and the day was just looking for direction after last week's all-time highs. Investors still have a lot of pressing issues and ...
Read Full Story »

Big Pharma Scares Off Short Sellers

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Big Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Unusual Settlement Deal Proposed for Opioid Lawsuits

Five pharmaceuticals makers are proposing an unusual method for settling hundreds of the more than 2,500 lawsuits facing drugmakers that made and sold opioid painkillers. The five companies want to ...
Read Full Story »